Addiction Treatment Insurance Denials: Appealing IOP and Residential Coverage Under MHPAEA

How MHPAEA classifies IOP, PHP, and residential care

The 2013 implementing regulations for MHPAEA (29 CFR § 2590.712) define six benefit classifications: (1) inpatient, in-network; (2) inpatient, out-of-network; (3) outpatient, in-network; (4) outpatient, out-of-network; (5) emergency care; (6) prescription drugs. The regulations do not create a seventh category for “intermediate” care. Instead, they require plans to assign intermediate behavioral health benefits — residential treatment, partial hospitalization (PHP), intensive outpatient (IOP) — to one of the existing six classifications in the same way they assign comparable intermediate medical-surgical benefits.

This classification requirement is the structural foundation of every level-of-care appeal. If a plan assigns residential SUD treatment to the inpatient classification, its medical necessity criteria for residential SUD cannot be more restrictive than the criteria it applies to comparable inpatient medical care — such as acute inpatient rehabilitation or sub-acute skilled nursing facility stays. If the plan assigns IOP to the outpatient classification, IOP criteria cannot be more restrictive than criteria for comparable outpatient programs like cardiac rehabilitation or intensive physical therapy.

Plans frequently get this wrong in practice. They apply their most restrictive proprietary utilization-review criteria to behavioral health intermediate care while applying more permissive criteria — or no comparable criteria at all — to analogous medical-surgical programs. That asymmetry is a non-quantitative treatment limitation (NQTL) in violation of 29 CFR § 2590.712.

For the mechanics of NQTL arguments and the broader MHPAEA framework, see the MHPAEA parity appeals guide. This guide focuses on the specific application to SUD and intermediate levels of care.

What the Collins v. Anthem settlement tells you about MCG criteria

In January 2026, a federal court approved a $12.88 million class action settlement in Collins et al. v. Anthem Inc. et al., No. 2:20-cv-01969 (E.D.N.Y.). The complaint alleged that Anthem's Clinical UM Guidelines and the MCG Guidelines for Residential Behavioral Health Level of Care were more restrictive than generally accepted medical-surgical standards of care — and thus violated both ERISA and MHPAEA.

The class covered anyone who, from April 29, 2017 through April 30, 2025, had a request for residential behavioral health or SUD treatment denied by Anthem on medical necessity grounds using those criteria. Class members who paid out of pocket for residential care after the denial may receive full reimbursement from the settlement fund; all other class members receive a minimum payment of $100.

MCG (formerly Milliman Care Guidelines) is a proprietary utilization-review product widely used by insurers, including Aetna, Cigna, and UnitedHealthcare in addition to Anthem. It is not the same as the American Society of Addiction Medicine (ASAM) Patient Placement Criteria, which are the clinical gold standard for SUD level-of-care decisions. ASAM criteria were developed by addiction medicine specialists as a patient-need assessment tool; MCG was developed as a cost-management instrument.

The practical consequence of the settlement: if your patient receives a residential SUD denial citing MCG criteria (or any criteria framed as “evidence-based” that deviate from ASAM), you have a federal precedent that a court found this exact pattern litigable under MHPAEA. The settlement does not create binding precedent, but it demonstrates that insurers have settled this argument for eight figures rather than litigate it to judgment. That value signal matters in an appeal.

Documenting the ASAM six-dimension assessment in your records

When a treating clinician documents the basis for a level-of-care recommendation using ASAM criteria, the appeal has a specific clinical anchor the plan must engage with. ASAM's Patient Placement Criteria assess six dimensions:

1. Acute intoxication and/or withdrawal potential
2. Biomedical conditions and complications
3. Emotional, behavioral, or cognitive conditions and complications
4. Readiness to change
5. Relapse, continued use, or continued problem potential
6. Recovery and living environment

If the clinical notes address each dimension and conclude that the patient meets ASAM criteria for the recommended level of care — and the insurer has denied that level citing MCG or proprietary criteria — the appeal should do four things: (1) document the ASAM assessment explicitly, (2) identify the specific criteria the plan applied, (3) argue those criteria are more restrictive than the ASAM clinical standard, and (4) invoke the MHPAEA NQTL framework requiring the plan to demonstrate it applies equally restrictive criteria to comparable medical-surgical intermediate care.

The ASAM documentation also matters for external independent review. IROs are required to apply generally accepted clinical standards; for SUD level-of-care, that standard is ASAM. An appeal record that maps clearly to ASAM dimensions gives the external reviewer a clinical basis to overturn the denial even if the internal appeal fails.

The CAA 2021 § 203 comparative analysis demand

Every level-of-care denial should include a written request for the plan's NQTL comparative analysis under § 203 of the Consolidated Appropriations Act of 2021 (codified at 29 U.S.C. § 1185a(a)(8)). This demand is statutory — it cannot be paused by executive action — and it shifts the burden to the plan to document in writing how its IOP, PHP, or residential SUD criteria are applied no more restrictively than criteria for comparable medical-surgical intermediate care.

For the full background on this demand, see the MHPAEA parity appeals guide. The level-of-care version of the demand:

Under § 203 of the Consolidated Appropriations Act of 2021, codified at 29 U.S.C. § 1185a(a)(8), I am requesting the plan's written comparative analysis of the non-quantitative treatment limitation applied to the denial of [residential treatment / IOP / PHP] for the above-referenced claim. The analysis must identify: (1) the specific criteria applied to this benefit classification for both mental health/SUD and medical-surgical benefits; (2) the evidence base for those criteria; and (3) the factors used to determine those criteria are applied no more restrictively to MH/SUD benefits than to comparable medical-surgical benefits. Please respond within 30 days. Failure to produce a defensible comparative analysis will be escalated to the relevant state and federal regulators.

Send by certified mail or via the plan's appeal portal with a tracking confirmation. Keep a copy with the date. Most plans cannot produce a defensible analysis when challenged on residential or IOP criteria — and the failure to produce one is itself evidence of a parity violation.

State-specific SUD parity rights

Three states have statutory language for SUD intermediate level-of-care that goes beyond federal MHPAEA. For fully-insured plans in these states, cite both the federal statute and the relevant state law.

California. SB 855 (Stats. 2020, ch. 151), effective January 2021 and amended through 2024, requires health insurers and HMOs to cover medically necessary treatment of SUD at all levels of care, including residential, PHP, and IOP. The plan cannot cap residential days or IOP sessions at levels that leave a gap between what ASAM criteria recommend and what the plan will pay. A denial that deviates from ASAM-supported clinical need is challengeable under SB 855 independent of the MHPAEA federal framework. See the California parity appeal guide for prompt-payment windows and DOI contact.

New York. New York Insurance Law § 3221(l)(5) imposes parity requirements specific to SUD and mental health residential treatment that, in some areas, exceed federal MHPAEA protections. The New York State Department of Financial Services has published guidance clarifying that plans may not apply visit limits or more restrictive criteria to SUD residential or IOP treatment than to comparable medical-surgical care.

Oregon. ORS 743A.168 requires parity for SUD services across benefit types. The Oregon Insurance Division has issued guidance that residential SUD criteria must comply with parity law, meaning the same threshold applies at the inpatient/residential tier for behavioral and medical-surgical care.

For all other states, 29 CFR § 2590.712 is the controlling standard. Check the per-state appeal guides for prompt-payment windows and insurance commissioner contacts.

When the appeal is denied: three parallel escalation paths

If the first-level internal appeal is denied, pursue all three escalation paths simultaneously rather than sequentially. Waiting for each response before filing the next one costs weeks and rarely improves the outcome.

External independent review (IRO). For residential, PHP, and IOP denials based on medical necessity or level-of-care criteria, federal law guarantees access to external review by a clinical reviewer with no relationship to the plan. IROs apply generally accepted clinical standards — for SUD, that means ASAM criteria. The IRO's decision is binding on the plan. File immediately after the first-level internal denial; a second internal appeal is rarely worth the time for level-of-care disputes.

State Department of Insurance complaint. For fully-insured plans, the state DOI has direct enforcement authority. A complaint that cites the specific level-of-care mismatch, the MCG vs. ASAM criteria argument, and the Collins v. Anthem settlement often gets a response from the plan within days — plans monitor DOI complaint queues closely. Find your state's DOI through the NAIC consumer locator.

DOL EBSA complaint (ERISA plans). File at askebsa.dol.gov. EBSA does not adjudicate individual cases but does pursue systemic parity violations. A filed complaint creates a documented record, and EBSA's enforcement focus on NQTL parity in 2026 means the agency is actively reviewing SUD level-of-care patterns.

FAQ